SITC 29th Annual Meeting: Lung Cancer - Immunology and ImmunotherapyNovember 7-9, 2014Gaylord National Hotel & Convention Center National Harbor, MDSession Co-Chairs Roy S. Herbst, MD, PhD – Yale Cancer Center Laurence Zitvogel, MD, PhD – Institute Gustave Roussy SITC 29th Annual Meeting Organizers Arthur A. Hurwitz, PhD - National Cancer Institute Kim A. Margolin, MD - Stanford University Daniel E. Speiser, MD - Ludwig Center for Cancer Research of the University of Lausanne Walter J. Urba, MD, PhD - Earle A. Chiles Research InstituteProgram SummaryLong thought to be non-immunogenic tumors, lung cancers have recently been shown to respond to immunotherapy via blockade of the PD-1:PD-L1 axis. This session at the 29th Annual Meeting on November 7, 2014 in National Harbor, MD discussed the exciting clinical results employing this strategy and describe other inhibitory pathways that may also be exploited. The accumulating evidence that the innate and adaptive immune systems make crucial contributions to the anti-tumor effects of conventional chemotherapy- and radiotherapy-based cancer treatments was discussed in reference to the development and clinical application of combined chemo-immunotherapy approaches. About the SITC 29th Annual MeetingThe SITC 29th Annual Meeting provided a multidisciplinary educational and interactive environment focused on improving outcomes for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy. The meeting consisted of cutting-edge research presentations by experts in the field, oral and poster abstract presentations, and ample opportunities for structured and informal discussions, including important networking opportunities. In addition, the meeting included updates on major national and international initiatives coming from academia, government and industry, as well as important society projects. #Biomarkers #ClinicalTrials #Non-SmallCellLungCancer #PresentationSlides #Video #AnnualMeeting #SITC #CombinationTherapy #ImmuneCheckpointInhibitors #Nivolumab #Pembrolizumab #AdverseEvents #Clinician #Industry #Oncologist #Researcher #2014
Meeting: SITC 29th Annual Meeting; Session: Lung Cancer: Immunology and Immunotherapy; Presentation: TG4010 Immunotherapy Combined with First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase IIb Results of the TIME Study; Presenter: John Nemunaitis, MD – Mary Crowley Medical Research Center; Date: November 7, 201400:11:46
Meeting: SITC 29th Annual Meeting; Session: Lung Cancer: Immunology and Immunotherapy; Presentation: PD-1 Immune Checkpoint Blockade: Patient Characteristics and Biomarkers Associated with Response; Presenter: Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Date: November 7, 201400:23:54
Meeting: SITC 29th Annual Meeting; Session: Lung Cancer: Immunology and Immunotherapy; Presentation: Personalized Immunotherapy for Non-Small Cell Lung Cancer; Presenter: Roy S. Herbst, MD, PhD – Yale Cancer Center; Date: November 7, 201400:26:54